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1. Introduction 
Three-dimensional printing (3DP) is an additive manufacturing process that can rapidly 
render 3D objects from computer aided design software by successively depositing polymeric 
materials layer by layer.[1] A range of different 3D printing technologies are in current use, 
with the most prevalent methodology using Fused Deposition Modelling (FDM) technology 
due to a synergetic combination that merges economic and accuracy/resolution factors.[2] In 
2015, Spritam
®
, a solid pharmaceutical formulation which contains the anti-epileptic drug 
levetiracetam, became the first 3D printed medicine approved by the US Food and Drug 
Administration (FDA) leading to a raised interest in this type of technology so to 
revolutionise healthcare in the area of personalised medicines.[3]  
Paracetamol, a Class III Biopharmaceutics Classification System drug (low permeability, 
high solubility), is a well-known analgesic and antipyretic drug that currently available in 
different pharmaceutical dosage forms including tablets, suspensions and solutions. Tablets 
are recurrently the most common accessible paracetamol containing formulation and are 
typically produced using the direct powder compression methodology or granulation, if 
segregation of powder constituents is a problem.[4-5] However, these manufacturing 
processes exhibit limitations when compared to the extrusion method of 3D printing. The 
most imperative limitation of the granulation method is lower active pharmaceutical 
ingredient (API) loading resulting in higher final product total weight and material loss 
during processing,[6] making 3D printing an appealing alternative method for tableting 
manufacturing.  
Few studies have investigated the production of paracetamol formulations using FDM 
printing,[7-8] Numerous studies have loaded drugs onto polymer filaments. Polyvinyl alcohol 
(PVA), frequently utilised in coatings for tablets, is a commonly used filament and 
impregnation of the drug is achieved by soaking the filament in a highly saturated drug 
solution. This method results in low drug loading (<2% w/w) because of slow drug diffusion 
into polymer.[9,10] The use of hot melt extrusion has been reviewed as an alternative method 
by Tan to increase drug loading of API onto filaments.[11] However, to date there are no 
direct comparisons of the release profiles of 3D printed paracetamol tablets and commercial 
tablets. PVA is one of the most widely used water-soluble synthetic polymers and was 
selected because of its excellent thermoplasticity and it is the only commercially extruded 
polymer filament that would dissolve in vivo.[9,12] Herein we demonstrate the preparation of 
3D printed paracetamol tablets using PVA, a biocompatible polymeric construct, and 
compare the drug release dissolution profile of the API with commercially available 
paracetamol containing tablets.  
 
2. Materials and Methods 
2.1 Materials 
Paracetamol USP grade, methanol (for HPLC, ≥99.9%) and potassium phosphate monobasic 
(KH2PO4) were purchased from Sigma–Aldrich Ltd, Gillingham, UK. Polyvinyl alcohol 
(PVA)was purchased from 3d FilaPrint, Southend-on-Sea, UK. Milli-Q water (resistivity 18.2 
MΩ cm) was used to produce all solutions. Paracetamol tablets were purchased from a 
pharmaceutical retailer (Boots, Nottingham, UK) with the following specifications: 
Paracetamol 500 mg Tablets (Batch No. 109T, Exp. Date. 08/2020, M&A Pharmachem Ltd, 
Bolton, UK). 
2.2 Methods 
2.2.1 Preparation of paracetamol-loaded PVA filament 
PVA filament was cut into small pieces and milled using a Krups F20342 grinder (KRUPS, 
Windsor, UK) and sieved through a 1000 µm mesh. The milled PVA (100 g) and paracetamol 
powder (100 g) were combined using a mortar and pestle until a homogenous mixture was 
produced. The mixture was then extruded using a single-screw filament extruder (Wellzoom 
desktop extruder filament B, Shanghai, China) to obtain a drug loaded filament (extrusion 
temperature: 200 °C; nozzle diameter: 3 mm; screw speed: 25 rpm). The extruded filament 
was stored in a vacuum desiccator (Nalgene®, Rochester, USA) and protected from light 
until printing. The drug-loading of the filament was determined by UV analysis. 
 
2.2.2 Additive manufactured paracetamol-loaded tablets printing specifications 
Tablets were fabricated using the aforementioned PVA drug-loaded filaments and a 
commercial fused-deposition modelling 3D printer, Ultimaker 2 (Ultimaker, Geldermalsen, 
Netherlands). Tablets were designed using the freeware web-based application Tinkercad 
(Autodesk, San Rafael, USA) software, exported as a standard tessellation language file 
(STL) and uploaded to the 3D printer software, Cura (Ultimaker, Geldermalsen, 
Netherlands). The 3D geometry of the tablet was cylindrical (12.83 mm diameter x 4.10 mm 
height). The fill density was set at 150% in order to produce solid dosage forms of high 
density. The printer settings that were found to produce the best tablets for PVA drug-loaded 
filament were of fine resolution, nozzle temperature (200 °C), nozzle diameter (0.4 mm), 
speed while extruding (30 mm/s), speed while travelling (30 mm/s), material flow (150%), 
number of shells (2), layer height (0.10 mm) and build plate temperature (60 °C). No 
supports or rafts were utilised in the printed model.  
2.2.3 UV analysis and quantification of paracetamol samples 
Paracetamol analysis was conducted using a Genova Plus UV/Visible spectrophotometer 
(Cole-Parmer, Staffordshire, UK). The UV readings were acquired at a wavelength of 242 
nm. A stock solution (24 μg mL-1) was prepared from a known amount of paracetamol 
dissolved in a 2% methanolic solution. The stock solution was diluted accordingly to prepare 
various concentrations of paracetamol ranging from 1.2 to 24 μg mL-1. A calibration curve 
was constructed with a linear relationship between concentration and absorbance with 
regression coefficient values (r
2
) of greater than 0.999. 
2.2.4 Testing conditions for tablet dissolution 
Tablet dissolution profiles for both commercially available and 3D printed formulations (n = 
3) were obtained using a USP II apparatus (Caleva 10ST, Erweka GmbH, Germany). The 
formulations were placed in 900 mL of a KH2PO4 buffer solution (pH 5.8, 0.032 M) for 60 
min to simulate the primary environment of the small intestine compartment. Paddle speed 
for USP II equipment was fixed at 50 rpm and the sampling conducted at 37 ± 0.5 °C under 
sink conditions. Aliquots from the dissolution media (1 mL) were taken at standardised time 
intervals and the volume replaced with fresh KH2PO4 buffer solution (pH 5.8, 0.032 M). 
Dissolution media samples were diluted to fit the calibration curve and paracetamol 
concentration was determined using the aforementioned UV analysis methodology. 
3. Results and Discussion 
Herein we show how PVA was used for the printing of tablets as a main polymeric filler. 
PVA is a well-known excipient used in the pharmaceutical industry acting as a binder in solid 
drug formulation.[13] This biocompatible polymer presents various desirable qualities for 
medicine manufacture such as high-water solubility  and tensile modulus (3500 MPa).[14] 
Unlike polycaprolactone (PCL), another biocompatible polymer with lower water solubility 
and extrusion temperature, PVA was shown to have positive FDM 3D printing capabilities 
which intend to recreate other important tablet properties (i.e. hardness, friability, 
disintegration (shown in the supplementary materials) and dissolution).[14] 
Paracetamol loaded PVA filament (3 mm) was successfully manufactured by blending a 
mixture of the API and PVA using hot melt extrusion. Tablets were initially fabricated using 
neat PVA filament to simulate the optimum conditions for 3D printing (Fig. 1A). Drug 
loaded printlets were similarly produced in cylindrical shape (Fig. 1B). The drug loading of 
the filament was 39%. This was lower than the theoretical value  as a result of adhesion of the 
fine API powder to the walls of the barrel of the HME during the extrusion process.[15] The 
tablets showed similar values to the filament indicating that no degradation took place during 
the printing process. Tablets also showed high uniformity in size and weight (mean 
dimensions: 12.93 mm diameter x 4.08 mm height, mean weight: 1.2459 g) which rendered a 
concise method of manufacture. Erokhin et al. have demonstrated that higher infill densities 
of 3D scaffolds reduce the shrinkage of polymers when printing thus resulting in marginally 
larger diameters in comparison to the original designs.[16] The height of the 3D printed 
construct shown here was comparable to the designed tablet, also demonstrating good 
adhesion between the printed layers. The dose of paracetamol in the 3D printed tablet was 
484.6 ± 18 mg in comparison to the commercial tablets that contained 500 ± 2 mg.   
 
 
Figure 1 - Printlets A) PVA and B) Paracetamol-loaded PVA. 
 
The dissolution profiles of commercial and PVA-loaded 3D printed paracetamol tablets were 
collected over a period of 60 minutes as shown in figure 2. The results gathered for the 
dissolution of the commercially available formulation met the guidelines set by the British 
Pharmacopeia,[17] whereby at least 80% of the active pharmaceutical ingredient (API) is 
released within 30 minutes. 
 
Figure 2 - Dissolution profiles for commercial (▲) and PVA-loaded 3D printed (■) tablets (n = 3, Mean ± SD) 
In comparison, the dissolution profile presented for the PVA-loaded 3D printed paracetamol 
tablets did not comply with the aforementioned guidelines since only 20.91 ± 0.32% of drug 
content was released from the formulation within 30 minutes and 30.61 ± 1.18% upon 
experimental completion (Fig. 2). In light of these results, further investigations were 
conducted to ascertain a more accurate paracetamol release profile. Consequently, PVA-
loaded 3D printed paracetamol tablets were left in dissolution testing conditions for a total 
period of 24 hours with results showing an extended release profile of the drug (63% drug 
release). Chai et al also demonstrated a similar trend in drug release rates for commercial and 
3D printed domperidone tablets, where 3% of the API was released from the 3D printed 
formulation after 15 minutes, with a sustained release profile emerging after 12 hours, 
although the drug loading was significantly lower.[18]  
4. Conclusions 
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Here we successfully demonstrate the 3D printing of paracetamol tablets using PVA loaded 
filament with a 100% infill density. The dissolution studies of the API from 3D printed 
paracetamol tablets showed a sustained release profile in comparison to commercial 
paracetamol tablets. This work exhibits the potential FDM printing brings to the manufacture 
of medicines, however high extrusion temperatures for PVA printing can be seen as a 
possible disadvantage and the use of alternative polymers may permit printing at lower 
temperatures to avoid degradation of the drug. Future studies will involve the potential use of 
different polymers and APIs with maintained biocompatibility and expected extend release 
profiles, respectively.    
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